两种质子泵抑制剂治疗幽门螺杆菌感染活动性胃溃疡的药物经济学评价

目的：应用药物经济学原理分析泮托拉唑与兰索拉唑治疗幽门螺杆菌（ Hp ）感染活动性胃溃疡成本-效果，寻找最佳治疗方案。方法：选择符合标准的患者100例，随机分为A组和B组各50例，A组应用泮托拉唑，B组应用兰索拉唑，其余治疗方案二者相同，疗程结束进行疗效评价。结果：A组患者临床治愈率80．00％，B组溃疡愈合率80．00％，差异无统计学意义（ P＞0．05）。 A组患者成本-效果比（C/E）为4．81，明显低于B组的5．81，增量成本-效果比（ΔC/ΔE）为68．33；敏感度分析A组患者C//E为4．33，明显低于B组的5．25，ΔC//ΔE为66．85。结论：泮托拉唑治疗幽门螺杆菌感染活动性胃溃疡较兰索拉唑具有更高的药物经济学价值。

Pharmacoeconomics Evaluation on 2 Proton Pump Inhibitors in Treatment of Active Stomach Ulcer Accompanied by Hp Infection

Objective：To analyze the cost-effectiveness ratios of pantoprazole and lansoprazole in treat-ment of active stomach ulcer accompanied by Hp infection with pharmacoeconomics principles and to search for the best treatment protocols .Method：100 patients meeting the criteria were selected and randomly divid-ed into group A and group B , 50 patients in each group .The patients in group A was treated with panto-prazole , while those in the group B treated with lansoprazole , the other treatment protocols of the two groups were the same , and the effects were evaluated in the end of the course of treatment .Result：The clinical re-covery rate of the group A and group B was 80.00%and 80.00%respectively , and the difference was statisti-cally insignificant （P＆gt;0.05）.The cost-effectiveness ratio （C/E） of the group A （4.81） was significantly lower than that of the group B （5.81）, and the incremental cost-effectiveness ratio （ΔC/ΔE） was 68.33;in sensitivity analysis, C//E of the patients of the group A （4.33） significantly lower than that of the group B （ 5.25）, and ΔC//ΔE was 66.85.Conclusion：Pantoprazole in treatment of active stomach ulcer accompa-nied by HP infection has higher pharmacoeconomics value than lansoprazole .